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Insulin-like growth factor-binding proteins (IGFBPs) are multifunctional proteins that 
possess IGF-dependent and -independent actions. Recent studies suggest that its 
IGF-independent action appeared early and that the IGF-binding function may have 
been acquired later in evolution. The timing of the emergence of IGF-dependent actions 
is unclear. Here, we identified and characterized an igfbp gene from sea lamprey, an 
agnathan, which was separated from the jawed vertebrates 450 million years ago. 
Phylogenetic and structural analyses suggested that the encoded protein belongs to 
the IGFBP-3 clade in the IGFBP family. Lamprey IGFBP-3 contains an IGF-binding 
domain (IBD), nuclear localization signal, and transactivation (TA) domain. Biochemical 
and functional analyses showed that these domains are all functional. Lamprey IGFBP-3 
can bind IGFs and modulate IGF signaling when tested in mammalian cells. Lamprey 
IGFBP-3 also has the capacity to enter the nucleus and has strong TA activity. Forced 
expression of lamprey IGFBP-3, but not its IBD mutant, in zebrafish embryos decreased 
body growth and developmental speed. Lamprey IGFBP-3 inhibited BMP2 signaling in 
cultured cells and in zebrafish embryos, and this action is independent of its IGF-binding 
function. These results suggest that lamprey IGFBP-3 has both IGF-dependent and 
-independent actions and provide new insights into the functional evolution of the IGFBP 
family.
Keywords: igFBP-3/igfbp-3, sea lamprey, ligand-binding domain, nuclear localization, transactivation activity, 
BMP2/Bmp2
inTrODUcTiOn
The insulin-like growth factor (IGF) system is an evolutionarily ancient hormonal pathway that plays 
fundamental roles in regulating development, growth, reproduction, and aging in vertebrates (1–3). 
The IGF signaling system consists of IGF ligands, IGF receptors, and IGF-binding proteins (IGFBPs) 
(2). IGFBPs bind IGF with high affinities and specificity. These proteins have several functions. They 
act as IGF carrier proteins in the blood and regulate IGF turnover, transport, and distribution. At the 
target tissues, IGFBPs inhibit and/or potentiate IGF actions by regulating IGF availability to the cell 
surface of IGF receptor (1–3). IGFBPs also possess IGF-independent actions. Some IGFBPs can be 
detected in the nucleus and has IGF-independent transactivation (TA) activity (3–7).
When and how these distinct biological functions evolved has long been a mystery. Earlier studies 
suggested a possible link between the evolution of IGFBP genes and the HOX genes. These genes are 
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neighboring genes on the same chromosomes (8, 9). Daza et al. 
recently proposed that a single ancestral chordate IGFBP gene 
underwent a local gene duplication, thereby resulting in a gene 
pair adjacent to a HOX cluster (10). Subsequently, the IGFBP 
gene family expanded in the two basal vertebrate tetraploidization 
events (2R), resulting in the six IGFBP types that are presently 
found in mammals (10). Indeed, a single IGFBP gene has been 
found in a basal chordate, amphioxus (8, 10). Amphioxus IGFBP 
shares major structural characteristics of vertebrate IGFBPs (11). 
However, the amphioxus IGFBP does not have the capability to 
bind to modern IGF-I or IGF-II, while it possesses the nuclear 
localization and transcriptional activation activity (11). Based 
on these and other data, it has been suggested that the IGF-
independent activities may be original and conserved functions, 
and the IGF-binding functions may have been acquired later in 
evolution (11). The timing of the emergence of IGF-dependent 
capacity is not clear.
Sea lamprey (Petromyzon marinus), an agnathan, occupies 
a key position in vertebrate evolution (12). Lamprey and the 
closely related hagfish are jawless fish, and they diverged from 
the jawed vertebrates (Gnathostomes) approximately 450 million 
years ago (12). The phylogenetic position of lampreys makes it 
an invaluable model for understanding the evolution of genes 
in vertebrates. Indeed, a single IGF peptide equally related to 
human IGF-I and IGF-II has been identified in the sea lamprey 
(13). Likewise, the related Atlantic hagfish also has a single IGF 
(14). We hypothesized that the IGFBPs may have evolved IGF-
dependent actions along with the emergence of IGF in agnathans. 
To test this hypothesis, we identified and characterized an igfbp 
gene from sea lamprey. This gene encodes lamprey IGFBP-3. 
Functional analyses showed that lamprey IGFBP-3 has both IGF-
dependent and -independent actions.
MaTerials anD MeThODs
Materials
Chemicals and reagents were purchased from Fisher Scientific 
(Pittsburgh, PA, USA), unless otherwise stated. RNA polymerase, 
RNase-free DNase, and pGEM-T easy vector were purchased from 
Promega (Madison, WI, USA). Taq DNA Polymerase, Phusion 
High-Fidelity DNA Polymerase, and restriction endonucleases 
were purchased from New England BioLabs (Beverly, MA, USA). 
M-MLV reverse transcriptase, oligo(dT)12–18 primers, and TRIzol® 
Reagent were purchased from Invitrogen Life Technologies, Inc. 
(Carlsbad, CA, USA). SMART™ RACE cDNA Amplification Kit 
was purchased from Clontech Laboratories, Inc. (Mountain View, 
CA, USA). mMESSAGE mMACHINE kit was purchased from 
Applied Biosystems/Ambion (Austin, TX, USA). IGF peptides 
were purchased from GroPep (Adelaide, SA, Australia) and 
IGFBP-3 and BMP-2 were from R&D systems (Minneapolis, MN, 
USA). The anti-GFP antibody was purchased from Torrey Pines 
Biolabs Inc. (East Orange, NJ, USA). Anti phospho-Smad1/5/8 
antibody was purchased from Cell Signaling Technology Inc. 
(Danvers, MA, USA). Total anti-Smad1/5/8 antibody was pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). Digoxigenin and anti-digoxigenin-POD antibodies were 
purchased from Roche (Indianapolis, IN, USA).
experimental animals
The sea lamprey (P. marinus) tissues were provided by Dr. 
Weiming Li, Michigan State University. Total RNA was extracted 
from the adult liver and used for cDNA synthesis. Wild-type 
zebrafish (Danio rerio) were maintained on a 14-h light/10-h 
dark cycle and fed twice a day. Embryos were obtained by natural 
cross. Fertilized eggs were raised at 28.5°C and staged according 
to Kimmel et  al. (15). 2-Phenylthiourea [0.003% (wt/vol)] was 
added to the embryo rearing solution in some experiments to 
inhibit embryo pigment formation. This study was approved by 
the Institutional Committee on the Use and Care of Animals, 
University of Michigan. It was carried out in accordance with 
the recommendation of the Institutional Committee on the Use 
and Care of Animals, University of Michigan. The protocol was 
approved by the Institutional Committee on the Use and Care of 
Animals, University of Michigan.
Molecular cloning
The human IGFBP-3 (NM_000598) and zebrafish Igfbp-3 
(NM_205751) amino acid (aa) sequences were used as queries to 
tblastn search the sea lamprey genome database.1 The best BLAST 
hits were collected, and their scaffold locations were determined. 
The genome sequence surrounding these best reads of short 
sequence was retrieved and used to predict the sea lamprey 
IGFBP-3 sequence using GENESCAN.2 The predicted protein 
sequence was searched by blastp.3 The full-length sequence of 
sea lamprey IGFBP-3 cDNA was determined by 5′- and 3′-rapid 
amplification of cDNA ends (RACE) using the SMART™ RACE 
cDNA Amplification Kit. The gene specific primers used were 
5′GSP1 and 5′NGSP1 for 5′ end amplification, and 3′GSP2 and 
3′NGSP2 for 3′ end amplification (Table S1 in Supplementary 
Material). The genomic structure of lamprey igfbp-3 was deter-
mined by the Blat program4 using the cloned full-length cDNA 
sequence and lamprey Assembly WUGSC 3.0.
sequence alignment and Phylogenetic 
analysis
The aa sequence of full-length lamprey IGFBP-3 and that of major 
IGFBPs (Table S2 in Supplementary Material) was aligned using 
BioEdit 7.0 (16). The same sequence information was used for 
subsequent phylogenetic tree construction. The following three 
bootstrap-supported tree construction methods were used: maxi-
mum likelihood (ML), Bayesian posterior probability (BayPP), 
and neighbor joining (NJ). The ML analysis was performed using 
ML 3.0 (17). ProtTest 2.4 was used to select the optimal model 
of aa substitution (18). The robustness of the ML was estimated 
by 1,000 bootstrap replications using the Jones–Taylor–Thornton 
(JTT) probability model. BayPP analysis was performed using 
MrBayes v.3.1 (19), assuming a four-category γ among site rate 
variation distribution, with uniform priors over trees, branch 
lengths (0.5), and the ASRV α parameter (0.05–10). A total of 
1 http://www.ensembl.org/Petromyzon_marinus/Info/Index.
2 http://genes.mit.edu/GENSCAN.html.
3 http://blast.ncbi.nlm.nih.gov/Blast.cgi.
4 http://genome.ucsc.edu/cgi-bin/hgBlat.
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1,000,000 generations were performed with four chains (Markov 
chain Monte-Carlo) and sampled for every 100 generations. The 
first 250 samples from each run, a point well past stationarity, 
were discarded as burn-in. All analyses converged on the same 
tree and found that the Jones protein model had 100% posterior 
probability. The NJ tree was constructed using MEGA4 (20) with 
JTT matrix in NJ method. The reliability of each tree node was 
assessed by the bootstrap method with 1,000 replications. The 
constructed trees were then visualized by TreeView (21).
synteny analysis
For synteny analysis, lamprey, zebrafish, and human IGFBP-
3/igfbp-3 gene, and their neighboring genes were extracted from 
Ensembl (Table S3 in Supplementary Material), and a schematic 
diagram was constructed to show locations of genes on each 
chromosome or scaffold.
Plasmid construction
The lamprey igfbp-3 open reading frame sequence was amplified 
by PCR using primers F1 and R1 (Table S1 in Supplementary 
Material) and cloned into pGEM-T easy vector and sequenced. 
It was then subcloned into pCS2+ and pCS2 + EGFP vectors 
using primers F2/R2 and F2/R3 (Table S1 in Supplementary 
Material), respectively. The lamprey IGFBP-3 IGF-binding 
domain (IBD) mutant was generated by changing R86, P87, L88, 
L91, and L92 to S, A, S, Q, and G using the primers IBDF and 
IBDR (Table S1 in Supplementary Material), according to Imai 
et  al. (22). The nuclear localization signal (NLS) mutant was 
generated by mutating 243RGRQR247 into MDGEA, the cor-
responding sequence of human IGFBP-1 (23), using primers 
NLSF and NLSR (Table S1 in Supplementary Material). The 
transactivation domain (TAD) mutants were generated by 
changing E25/D28/E48/P49/E70 into the corresponding residues 
of human IGFBP-1 (24) by three rounds of mutagenesis using 
primers TAD1F/TAD1R, TAD2F/TAD2R, and TAD3F/TAD3R 
(Table S1 in Supplementary Material).
To analyze their possible TA activity, lamprey IGFBP-3 and 
its N-domain were fused to Gal4 DNA-binding domain (DBD). 
Briefly, DNA fragments encoding lamprey IGFBP-3 and its 
N-domain were amplified by PCR using primers shown in Table 
S1 in Supplementary Material. The PCR products were cloned 
into the BamHI site of the pBind vector, thereby fusing the frag-
ments in frame to the C-terminus of Gal4DBD.
cell culture, One-hybrid Transcription 
activation assay, and subcellular 
localization
Human embryonic kidney (HEK) 293T cells, U2 osteosarcoma 
(U2OS) cells, and HeLa cells, purchased from the American 
Type Culture Collection (Manassas, VA, USA), were cultured 
as reported previously (25). HEK293 cells were used in cell 
proliferation and one-hybrid assays because they are fast grow-
ing and easy to transfect. HeLa cells are flattened cells with a 
large nucleus, and they were used in the subcellular localization 
experiment. U2OS cells have been previously used to study 
BMP2 signaling (26).
For one-hybrid transcription activation assay, 500  ng of 
pBind or pBind-IGFBP DNA and 500 ng of pG5-luc DNA were 
co-transfected into HEK293T cells as reported previously (24). 
Twenty-four hours after transfection, cells were washed with 
PBS and lysed in lysis buffer. The firefly and Renilla luciferase 
activities were determined using the Dual-Luciferase Reporter 
assay system (Promega). For subcellular localization studies, 
EGFP, lamprey IGFBP-3, and its various mutants–EGFP fusion 
constructs were transfected into HeLa cells. Transfected cells 
were fixed by PFA, stained by DAPI, and then imaged as previ-
ously reported (26).
conditioned Medium (cM), Western 
immunoblotting, and ligand Blotting
To obtain the CM, lamprey IGFBP-3, its various mutants, or 
human IGFBP-3 plasmid DNA (2 µg) were transfected into HEK 
293T cells. Twenty-four hours later, cells were washed three times 
with PBS and changed to serum-free medium. After incubation 
for 48 h, the CMs were collected and centrifuged to remove cellu-
lar debris. These CMs were subjected to western immunoblotting 
and ligand blotting analyses as described previously (26). Human 
IGF-I was labeled with digoxingenin following the published 
methods (27).
cell Proliferation and igF signaling  
assays
To determine the possible IGF-dependent action of lamprey 
IGFBP-3, HEK293T cells were plated into 96-well plates in 
DMEM supplemented with 10% fetal bovine serum. After incu-
bated for 1  day, cells were rinsed three times with serum-free 
DMEM. One hundred microliters of CMs collected from cells 
transfected with lamprey IGFBP-3, its IBD mutant, or human 
IGFBP3 were mixed with 100  µl of DMEM with or without 
IGF-I (with a final concentration of 100 ng/ml) and incubated 
for 30 min at room temperature. The mixed media were added 
to cells. Forty-eight hours later, cell numbers were assayed 
using a cell counting kit from ZOMANBIO (Beijing) following 
the manufacturer’s instruction. To study the effect of lamprey 
IGFBP-3 on IGF-I-induced pAkt signaling, HEK293T cells were 
plated into 24-well plates and treated as described above. The 
cells were harvested after 3 h of treatment. The cell lysates were 
analyzed by immunoblotting using antibodies against pAkt and 
total Akt.
BMP2 signaling assay
Human U2OS cells were seeded into 24-well plates. After 24 h, the 
cells were washed and incubated in serum-free medium for 3 h. 
Then, 100 µl of DMEM containing human BMP2 (20 ng/ml) were 
mixed with 100 µl of CMs as described and added to the cells. 
After 3  h, cells were harvested in RIPA buffer containing pro-
tease and phosphatase inhibitors (10 µg/ml aprotinin, 10 µg/ml 
leupeptin, 10  µg/ml pepstatin, 1  mM PMSF, 1  mM sodium 
orthovanadate, and 1  mM sodium fluoride) and subjected to 
immunoblotting using antibodies against pSmad1/5/8 and total 
Smad1/5/8.
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Microinjection experiment and real-time 
Quantitative rT-Pcr (qrT-Pcr) analysis
Capped mRNA was synthesized using a commercial mMESSAGE 
mMACHINE kit and linearized plasmid DNA as template. Two 
hundred picograms of mRNA encoding EGFP, lamprey IGFBP-
3, and its various mutants, 50 pg of mRNA encoding zebrafish 
Chordin, and 2.5 pg of mRNA encoding zebrafish Bmp2b were 
microinjected into zebrafish embryos at one to two cell stages, 
respectively. Intact embryos were used as controls. After micro-
injection, embryos were raised in embryo rearing medium (28) 
and kept at 28.5°C. Live embryos were imaged, and body length 
and somite number were determined at 24 hpf.
For qRT-PCR analysis, total RNA was extracted using TRIzol® 
Reagent following the manufacturer’s instruction. After DNase 
treatment, RNA (1 µg) was reverse transcribed with oligo(dT)18 
primers and M-MLV reverse transcriptase. qRT-PCR was 
performed in an iCycler iQ Multicolor real-time PCR detection 
system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using 
SYBR® Premix Ex Taq™ (Takara Bio Inc., Dalian, Liaoning). 
Primer pairs used for qPCR were as follows: tp63F/tp63R for 
tp63 and actinF/actinR for β-actin (Table S1 in Supplementary 
Material). Each sample was measured in duplicate. Target gene 
mRNA levels were calculated using the 2−ΔΔCT method (29) and 
presented as relative (-fold) values of the control group after being 
normalized by β-actin mRNA levels.
statistical analysis
Values are presented as means ± SD. Differences among groups 
were analyzed using one-way ANOVA followed by the Turkey’s 
multiple comparison test. All analyses were performed using 
GraphPad Prism version 5.01 (San Diego, CA, USA). Significance 
was accepted at P < 0.05 or higher.
resUlTs
identification and characterization of sea 
lamprey igfbp-3
Our search of the sea lamprey genome database identified an 
igfbp-like gene (ENSPMAG00000004139) on scaffold GL476421 
(previously known as Contig6676.1). Using RACE, the full-length 
cDNA was obtained and sequenced. The genomic structure was 
determined. This lamprey gene contains four exons and three 
introns (Figure  1A). There are two polyadenylation signal 
sequence (Figure 1A). Thus, the full-length cDNAs are 2,111 bp 
(KX904869) and 1,894 bp (KX904870), respectively. The putative 
signal peptide is 32 aa and mature protein is 278 aa with a pre-
dicted molecular mass of 29.8 kDa. There are 12 cysteine residues 
in the highly conserved N-terminal domain (residues 1–101) 
and 6 cysteine residues in the conserved C-terminal domain 
(residues 200–278) (Figure  1B). A conserved IGFBP motif is 
present in its N-domain and a thyroglobulin type 1 repeat in the 
C-domain (Figure  1B). This protein has the highest sequence 
identities with IGFBP-3/Igfbp-3 in the IGFBP family (Table S4 
in Supplementary Material). Phylogenetic analyses have placed 
this lamprey IGFBP in the IGFBP-3 clade (Figure  1C; Figures 
S1 and S2 in Supplementary Material). Therefore, we named this 
gene as lamprey igfbp-3. The lamprey igfbp-3 is located on scaf-
fold GL476421 (Figure 1D). In human and zebrafish genomes, 
IGFBP-3/igfbp-3 gene is located next to IGFBP-1/igfbp-1, arranged 
with a tail-to-tail orientation (Figure  1D). We were unable to 
find any igfbp-1-like gene in lamprey scaffold GL476421. An 
ACDY1 orthologous gene was found in GL476421 in this scaffold 
(Figure 1D).
lamprey igFBP-3 has a Functional iBD, 
nls, and TaD
The IGF-binding domain (IBD), TAD, and NLS are found in 
lamprey IGFBP-3 (Figure  1B). To determine whether these 
motifs are functional, they were mutated and tested functionally 
(Figure S3 in Supplementary Material). Ligand blotting assay 
showed that lamprey IGFBP-3, but not its IBD mutant, was able 
to bind human IGF-I (Figure 2A). The NLS and TAD mutants 
were also able to bind IGF-I (Figure 2A). The expression levels of 
these fusion proteins were similar (Figure 2A). When expressed 
in HeLa cells, the lamprey IGFBP-3-GFP signal was observed 
exclusively in the nucleus (Figure 2B). The IGFBP-3 IBD mutant 
and TAD mutant had similar nuclear. Mutation of NLS, on the 
other hand, abolished the nuclear localization (Figure 2B), sug-
gesting that the lamprey IGFBP-3 NLS is functional. Next, one-
hybrid TA assay was performed. Lamprey IGFBP-3 N-domain 
(BP3-N) caused a 16-fold increase in GAL4-dependent TA 
activity (Figure  2C). As the case in human IGFBP-3 (30), the 
full-length lamprey IGFBP-3 had no such activity, indicating that 
its activity is masked by its N-domain (Figure  2C). Next, the 
lamprey TAD sequence was mutated to corresponding sequence 
in human IGFBP-1, which had no TA activity (24). The TAD 
mutant had significantly reduced TA activity (Figure 2C). These 
results indicate that the IBD, NLS, and TAD in lamprey IGFBP-3 
are functional.
lamprey igFBP-3 has igF-Dependent 
action
We tested whether lamprey IGFBP-3 has IGF-dependent action 
in cultured human cells because it is technically difficult to 
perform functional studies in lamprey. Lamprey IGFBP-3 and its 
IBD mutant expression plasmids were transfected into HEK293T 
cells. Human IGFBP-3 plasmid and empty vector transfected cells 
were used as controls. Addition of IGF-I significantly stimulated 
HEK293T cell proliferation (Figure  3A). Co-incubation with 
lamprey IGFBP-3 inhibited IGF-I-induced cell proliferation 
(Figure  3A). The inhibitory effect was comparable to that of 
human IGFBP-3 (Figure  3A). Likewise, both lamprey and 
human IGFBP-3 inhibited IGF-I-induced Akt phosphorylation 
(Figure 3B). The lamprey IGFBP-3 IBD mutant had no effect on 
IGF-I-induced cell proliferation or pAkt signaling (Figures 3A,B), 
suggesting that this action of lamprey IGFBP-3 requires its IBD 
domain.
We next investigated whether lamprey IGFBP-3 has IGF-
dependent action in  vivo in zebrafish embryos by mRNA 
injection experiments. As shown in Figure  4A, the EGFP 
mRNA-injected embryos were indistinguishable from the WT 
embryos. Forced expression of lamprey IGFBP-3 significantly 
FigUre 1 | structural, phylogenetic, and synteny analysis of lamprey igFBP-3. (a) The genomic structure of lamprey igfbp-3. The two PolyA signals are 
indicated by vertical lines. (B) Comparison of lamprey IGFBP-3 (IGFBP-3 Pm) amino acid (aa) sequence with that of human IGFBP-3 (IGFBP-3 Hs), mouse IGFBP-3 
(IGFBP-3 Mm), chicken IGFBP-3 (IGFBP-3 Gg), and zebrafish Igfbp-3 (Igfbp-3 Dr). Hyphens were inserted for optimal alignment. The identical aas are dark shaded, 
and similar ones are gray shaded. Signal peptide, N-domain, L-domain, and C-domain are separated by vertical lines. The IGF-binding domain (IBD) and nuclear 
localization signal (NLS) are indicated by open boxes. The insulin-like growth factor binding protein (IGFBP) and thyroglobulin type I motifs are underlined. The aas 
known to be critical for transactivation activity in human IGFBPs are indicated by asterisks. (c) Phylogenetic analysis. Maximum likelihood (ML) was performed on a 
matrix composed of full-length aa sequences of major IGFBPs. ML bootstrap values shown are percentage of times that the two clades branched as sisters. 
Amphioxus IGFBP (IGFBP Bb) was used as the outgroup. (D) Synteny analysis. The IGFBP-3/igfbp3 genes are indicated in orange, while their neighboring genes 
are black. The chromosome or scaffold number and the location of IGFBP-3/igfbp3 and its neighboring genes are shown. Lines indicate orthologous genes.
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decreased body length (Figures  4A,B)  and somite number 
(Figures 4A,C). Similar effects were seen with the TAD and NLS 
mutants (Figures  4A–C). Mutation of the IBD abolished this 
action (Figures 4A–C), suggesting that this action is primarily 
IGF-binding dependent.
lamprey igFBP-3 has igF-independent 
Function
We have previously reported that human and zebrafish IGFBP-3/
Igfbp-3 can antagonize BMP action, and this action is independent 
of its IGF-binding function (26). To investigate whether lamprey 
IGFBP-3 has this activity, co-incubation experiments were car-
ried out. Addition of human BMP-2 strongly induced Smad1/5/8 
phosphorylation in cultured human U2OS cells (Figure  5A). 
Co-incubation with CMs containing lamprey IGFBP-3, zebrafish 
Igfbp-3, or human IGFBP-3 strongly inhibited BMP-2-induced 
Smad1/5/8 phosphorylation (Figure  5A). The CMs from the 
empty vector transfected cells had no such effect (Figure 5A).
Next, mRNA injection experiments were carried out. Injection 
of Bmp2b mRNA resulted in an eightfold and highly significant 
increase in the mRNA levels of tp63 (Figure 5B), a known Bmp 
target gene (31). Injection of Bmp2b with Chordin mRNA, a 
well-known Bmp antagonist, significantly reduced tp63 mRNA 
expression (Figure  5B). Likewise, injection lamprey IGFBP-3 
mRNA resulted in a significant decrease in tp63 mRNA expres-
sion (Figure 5B). This effect was comparable to those of human 
IGFBP-3 and zebrafish Igfbp-3 (Figure 5B). Importantly, the lam-
prey IGFBP-3 IBD mutant had similar effect (Figure 5B). These 
results suggest that lamprey IGFBP-3 has the ability to antagonize 
Bmp signaling and this action is IGF independent.
FigUre 2 | lamprey igFBP-3 contains a functional iBD, nuclear 
localization signal (nls), and transactivation domain (TaD). (a) Ligand 
blotting (upper panel) and immunoblotting (lower panel) analyses of lamprey 
IGFBP-3, its IBD, NLS, and TAD mutants. DIG-labeled human IGF-I and 
anti-GFP antibodies were used, respectively. (B) Subcellular localization of 
lamprey IGFBP-3, its IBD, NLS, and TAD mutants in HeLa cells. The EGFP 
signal was visualized 24 h after transfection (left panel). Corresponding DAPI 
staining is shown in the middle column and merged views in the right 
column. Scale bar = 50 µm. (c) Lamprey IGFBP-3 N-domain has strong 
transactivation (TA) activity. Lamprey IGFBP-3 N-domain (IGFBP-3-N), its TAD 
mutants (TAD-N), and full-length lamprey IGFPB-3 were fused to pBIND and 
transfected into HEK293T cells together with a Gal4 reporter plasmid. The TA 
activity is expressed as fold increase over the pBind control group. Values are 
expressed as means ± SD (n = 3). Groups with different letters are 
significantly different from each other (P < 0.05).
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DiscUssiOn
Insulin-like growth factor-binding proteins were initially dis-
covered based on their ability to directly bind with IGF-I and/
or -II. All vertebrate IGFBPs studied to date can bind to IGF-I 
and/or IGF-II with high affinity (2). Subsequent studies revealed 
that several IGFBPs, including IGFBP-3, also possess IGF-
binding-independent functions. Although all known IGFBPs 
are secreted proteins, some are also found in the nucleus and 
possess IGF-independent TA activities (24, 30, 32, 33). A recent 
study suggested that while amphioxus IGFBP has the nuclear 
localization and TA activity, it lacks the IGF-binding function 
(11). This has led to the idea that the nuclear localization and 
transcription activation activity of IGFBPs appeared early and 
the IGF-binding function may have been acquired by opportun-
istic gain-of-functional mutations later in evolution (11). When 
did the IGF-dependent action emergence, however, was unclear. 
In this study, we sought to determine whether IGF-dependent 
action was evolved before or after divergence of agnathans from 
jawed vertebrates by identifying and characterizing IGFBP-
like molecules from sea lamprey. In this study, we identified 
and cloned an igfbp gene from this species. Phylogenetic and 
structural analyses showed that this lamprey gene is most closely 
related to mammalian IGFBP-3.
IGFBP-3 is a multifunctional protein. It is the predominant 
IGFBP in the blood and functions as the major IGF carrier protein 
in the circulation. IGFBP3 is also expressed in many peripheral 
tissues and has also been shown to inhibit and/or potentiate 
the actions of IGF in a wide variety of tissues (32). Moreover, 
IGFBP-3 has been reported to possess IGF-independent actions. 
Mammalian and other vertebrate IGFBP-3 studied to date all con-
tain several functional motifs/domains, including IBD, NLS, and 
TAD. Structural analysis suggested that all these motifs/domains 
are conserved in lamprey IGFBP-3. The primary IGF-binding site 
(R/KPLXXLL) is located in the N-domain in mammalian and 
zebrafish IGFBP-3s (22, 26). This sequence is perfectly conserved 
in lamprey IGFBP-3. Our ligand blot analysis results showed 
that lamprey IGFBP-3 indeed can directly bind to human IGF-I. 
Mutation of the IBD sequence in lamprey IGFBP-3 impaired its 
IGF-binding action. Importantly, lamprey IGFBP-3 has the ability 
to modulate IGF action when tested in zebrafish embryos in vivo 
and human cells in  vitro, while its IBD mutant cannot. These 
structural and functional analysis results argue strongly that the 
IGF-binding function of IGFBPs have evolved prior to the emer-
gence of agnathans. This speculation is in good agreement with 
the current understanding of the evolution history of insulin/IGF 
peptides. It is believed that the IGFs are derived from an ancestral 
insulin-like gene that has duplicated and diverged many times 
throughout metazoan evolution, yielding insulin and the IGFs, 
in addition to a number of insulin-like peptides (34). To date, 
IGF-like molecules have not been identified in any invertebrate. 
Agnathans such as lamprey and hagfish apparently have only 
one IGF that has features characteristic of both IGF-I and IGF-II 
(13, 14). In primitive jawed vertebrates such as elasmobranch 
(e.g., shark), two distinctive IGF-like peptides appear: one is more 
similar to mammalian IGF-I molecules, while the other is more 
like IGF-II (35). These observations have lead to the proposal 
that IGF-like molecule emerged prior to or at agnathans and then 
separated into IGF-I and IGF-II in jawed fish. Our finding on 
the IGF-binding and IGF-dependent action of lamprey IGFBP-3 
agrees well with this scenario. It should be pointed out that 
human IGF-I was used, and the biological assays were performed 
FigUre 3 | lamprey igFBP-3 has insulin-like growth factor (igF)-dependent action in vitro. (a) Lamprey IGFBP-3, but not its IBD mutant, inhibits 
IGF-I-stimulated cell proliferation. Confluent HEK293T cells were treated with IGF-I together with conditioned media prepared from cells transfected with the empty 
vector, lamprey IGFBP-3, its IBD mutant, and human IGFBP-3, respectively. The values are expressed as means ± SD (n = 3). Groups with different letters are 
significantly different from each other at P < 0.05. (B) Lamprey IGFBP-3, but not its IBD mutant, inhibits IGF-I-induced pAkt signaling. HEK293T cells were treated 
as described in panel (a). Cells were harvested and analyzed by western immunoblotting using indicated antibodies. Similar results were obtained in two additional 
and independent experiments.
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FigUre 4 | lamprey igFBP-3 has insulin-like growth factor-dependent action in vivo. (a) Representative images of 24 hpf embryos injected with mRNA 
encoding the indicated proteins. Wild-type (WT) embryos were used as controls. Scale bar = 0.5 mm. Body length (B) and somite number (c) of the 
abovementioned groups were quantified and shown. Values are represented as means ± SD (n = 3). The total number of embryos in each group is shown on the 
top of each column. Groups with different letters are significantly different from each other (P < 0.05).
in human cells and zebrafish embryos. Future studies are needed 
to further address this issue using pure and biologically active 
lamprey IGF and in lamprey.
Mammalian and zebrafish IGFBP-3/Igfbp-3 has a functional 
NLS and can be found in the nucleus of cultured tumor cells 
(3, 4, 26). When tested in mammalian cells, human and zebrafish 
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IGFBP-3 both showed strong TA activity (26, 30). These functions 
have been attributed to a conserved NLS in the C-domain and a 
TAD in the N-domain of IGFBP-3. In this study, we investigated 
whether the NLS and TAD are present and functional in lamprey 
IGFBP-3. Our results suggested that lamprey IGFBP-3 N-domain 
has TA activity when tested in mammalian cells. A 50% reduc-
tion in TA activity was observed when several conserved acidic 
residues were mutated, suggesting that other residues may also 
contribute to the TA activity. Lamprey IGFBP-3 can localize 
into the nuclei of mammalian cells, and this nuclear localization 
activity was abolished when NLS was mutated. In comparison, 
the IBD mutant and TAD mutant protein showed normal nuclear 
localization activity. These results suggest that the TAD and NLS 
are conserved and functional in agnathans.
We have previously reported that human and zebrafish 
IGFBP-3/Igfbp-3 can antagonize BMP action in zebrafish 
embryos, and this action is independent of its IGF-binding 
function (26). We used this in  vivo assay system to further 
investigate the ligand-independent action of lamprey IGFBP-3. 
Forced expression of lamprey IGFBP-3 increased the mRNA 
expression of tp63, a known Bmp target gene. This action 
was indeed independent from IGF-binding because lamprey 
IGFBP-3 IBD mutant had similar effect. When tested in cultured 
human cells, lamprey IGFBP-3 had a similar inhibitory effect 
on BMP2-induced Smad signaling. This effect was comparable 
to those of human IGFBP-3 and zebrafish Igfbp-3. Collectively, 
these data indicate that lamprey IGFBP-3 has an evolutionarily 
conserved ability to antagonize Bmp signaling and this action is 
IGF independent.
In summary, lamprey IGFBP-3 can bind IGFs and modulate 
IGF signaling when tested in mammalian cells. Forced expression 
of lamprey IGFBP-3, but not its IBD mutant, in zebrafish embryos 
decreased body growth and developmental timing. Lamprey 
IGFBP-3 also has the capacity to enter the nucleus and has strong 
TA activity. When tested in human cells and zebrafish embryos, 
lamprey IGFBP-3 inhibited BMP2 signaling, and this action is 
independent of its IGF-binding function. These findings suggest 
that lamprey IGFBP-3 has both IGF-dependent and -independ-
ent actions and have provided new insights into the functional 
evolution of the IGFBP family. Future studies will determine the 
presence, structure, and function of other IGFBPs in lamprey to 
gain a better understanding of the evolution of the IGFBP gene 
family.
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FigUre 5 | lamprey igFBP-3 antagonizes BMP signaling independently of its insulin-like growth factor-binding function. (a) IGFBP-3 inhibits BMP-2 
signaling in vitro. Human U2 osteosarcoma cells were treated with 10 ng/ml of human BMP2 plus the indicated conditioned media. Three hours later, the cells were 
harvested and analyzed using the indicated antibodies. A representative image of western immunoblotting is shown on the top and quantitative results in the lower 
panel. pSmad1/5/8 level was normalized by total Smad1/5/8 level. Values are expressed as means ± SD (n = 3). Groups with different letters are significantly 
different from each other (P < 0.05). (B) IGFBP-3 inhibits BMP-2 signaling in vivo. Zebrafish embryos were injected with the indicated capped mRNA. Seven hours 
after injection, embryos were pooled. RNA was extracted and analyzed by quantitative RT-PCR. Wild-type (WT) embryos were used as control. Values are 
expressed as means ± SD (n = 3). Groups with different letters are significantly different from each other at P < 0.05.
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